var data={"title":"C1 esterase inhibitor, concentrate from human plasma: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">C1 esterase inhibitor, concentrate from human plasma: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/367710?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=c1-esterase-inhibitor-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">see &quot;C1 esterase inhibitor, concentrate from human plasma: Drug information&quot;</a> and <a href=\"topic.htm?path=c1-esterase-inhibitor-concentrate-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">see &quot;C1 esterase inhibitor, concentrate from human plasma: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6759053\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Berinert;</li>\n      <li>Cinryze;</li>\n      <li>Haegarda</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13261898\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Berinert;</li>\n      <li>Cinryze;</li>\n      <li>Haegarda</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7715627\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Blood Product Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7715637\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=c1-esterase-inhibitor-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">see &quot;C1 esterase inhibitor, concentrate from human plasma: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Products are not interchangeable.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hereditary angioedema (HAE) attacks; routine prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cinryze: Children &ge;6 years (limited data available) and Adolescents: IV: 1,000 units every 3 to 4 days (ie, twice weekly) (Lumry 2013); according to the manufacturer's labeling, in adolescents and adults if an adequate response it not achieved, doses up to 2,500 units (&le;100 units/kg/dose) every 3 to 4 days may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Haegarda: Adolescents: SubQ: 60 units/kg/dose every 3 or 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hereditary angioedema (HAE) attacks (abdominal, facial or laryngeal); treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Berinert: Children &ge;5 years and Adolescents: IV: 20 units/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cinryze: Limited data available: Children &ge;6 years and Adolescents: IV: 1,000 units; may repeat dose in 1 hour if needed (Lumry 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hereditary angioedema (HAE) attacks; routine prophylaxis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cinryze: IV: 1,000 units every 3 to 4 days; doses &le;2,500 units (&le;100 units/kg) every 3 or 4 days may be considered based on individual patient response.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Haegarda: SubQ: 60 units/kg every 3 or 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hereditary angioedema (HAE) attacks (abdominal, facial, or laryngeal); treatment:</b> Berinert: IV: 20 units/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764799\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Berinert: 500 units</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cinryze: 500 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Haegarda: 2000 units (1 ea); 3000 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764774\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11368727\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Assistance with procurement and reimbursement of Cinryze is available for health care providers and patients through the CINRYZESolutions program (telephone:1-877-945-1000) or at http://www.cinryze.com/Cinryze_Solutions/Default.aspx</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7715638\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Berinert: A silicone-free syringe is recommended for administration. Administer IV at recommended infusion rate: 4 mL/minute (200 units/minute); use within 8 hours of reconstitution; discard any unused product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cinryze: A silicone-free syringe is recommended for administration. Administer IV at recommended infusion rate: 1 mL/minute (over 10 minutes; 100 units/minute); use within 3 hours of reconstitution; discard any unused product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Self-administration: Following patient or caregiver training and instructions on self-administration, patient or caregiver may self-administer treatment (Berinert) or prophylaxis (Cinryze) therapy. Epinephrine should be available during self-administration in the event of an acute, severe hypersensitivity reaction. Patient suffering from an acute laryngeal HAE attack and self-administering should be informed to seek immediate medical attention following treatment (potential for airway obstruction to occur).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Haegarda: A silicone-free syringe is recommended for administration. Administer SubQ in the abdominal area or other SubQ injection sites. Rotate injection sites. Use within 8 hours of reconstitution; discard any unused product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Self-administration: Following patient training and instructions on self-administration, patient may self-administer prophylaxis therapy. Epinephrine should be available during self-administration in the event of an acute, severe hypersensitivity reaction. Patient suffering from an acute laryngeal hereditary angioedema (HAE) attack and self-administering should be informed to seek immediate medical attention following treatment (potential for airway obstruction to occur).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764787\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Berinert, Cinryze: Store intact vials at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F); do not freeze. Store in original carton; protect from light. Use within 3 hours (Cinryze) or 8 hours (Berinert) of reconstitution (Canadian labeling recommends immediate use after reconstitution); do not refrigerate or freeze reconstituted solution. Discard any unused product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Haegarda: Store intact vials at &le;30&deg;C (86&deg;F); do not freeze. Store in original carton; protect from light. Use within 8 hours of reconstitution; do not refrigerate or freeze reconstituted solution. Discard any unused product.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7715628\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Berinert: Treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) (FDA approved in pediatric patients [age not specified] and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cinryze, Haegarda: Routine prophylaxis against angioedema attacks in patients with HAE (FDA approved in adolescents and adults); Cinryze has also been used for treatment of acute abdominal, facial, and laryngeal attacks of HAE</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764808\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, abdominal pain, dysgeusia, nausea, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema (including exacerbation of hereditary angioedema), hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Fungal infection (vulvovaginal), viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Flu-like symptoms, nasopharyngitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, infusion-related reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, anxiety, cerebrovascular accident, chest pain, chills, deep vein thrombosis, diarrhea, fatigue, malaise, migraine, pain, shock, sinusitis, swelling, thrombosis, transient ischemic attacks, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764780\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of anaphylactic or life-threatening hypersensitivity reactions to human C1 inhibitor or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764781\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Severe hypersensitivity reactions (eg, urticaria, hives, tightness of the chest, wheezing, hypotension, anaphylaxis) may occur during or after administration. Signs/symptoms of hypersensitivity reactions may be similar to the attacks associated with hereditary angioedema, therefore, consideration should be given to treatment methods. In the event of acute or severe hypersensitivity reactions, discontinue treatment immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Serious arterial and venous thromboembolic events have been reported at recommended intravenous doses and when used off-label at doses higher than recommended. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Consider potential risk of thrombosis with use, and closely monitor patients with preexisting risks for thrombotic events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Human plasma: Product of human plasma; may potentially contain infectious agents (eg, viruses, the variant Creutzfeldt-Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent) that could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-administration: Due to the potential for airway obstruction, patients suffering from an acute laryngeal hereditary angioedema (HAE) attack and self-administering should be informed to immediately seek medical attention following treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298919\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764785\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16458&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the thrombogenic effect of C1 inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May enhance the thrombogenic effect of C1 inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May enhance the thrombogenic effect of C1 inhibitors.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764777\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764778\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Although information related to use during pregnancy is limited, plasma-derived human C1 inhibitor concentrate is the preferred treatment for HAE during pregnancy (Baker 2013; Caballero 2012). Women with HAE should be monitored closely during pregnancy and for at least 72 hours after delivery (Caballero 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11598643\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor patient closely for hypersensitivity reaction and thrombotic events during or after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764789\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">C1 inhibitor, one of the serine proteinase inhibitors found in human blood, plays a role in regulating the complement and intrinsic coagulation (contact system) pathway, and is also involved in the fibrinolytic and kinin pathways. C1 inhibitor therapy in patients with C1 inhibitor deficiency, such as HAE, is believed to suppress contact system activation via inactivation of plasma kallikrein and factor XIIa, thus preventing bradykinin production. Unregulated bradykinin production is thought to contribute to the increased vascular permeability and angioedema observed in HAE.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6764790\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Cinryze: Increased plasma C1 inhibitor levels observed ~1 hour or less</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of symptom relief: Berinert: Median: 15 minutes per attack; Cinryze: Pediatric patients 6 to 17 years: Median: 30 minutes per attack; for the majority of patient unequivocal symptom relief reported within 1 hour (range: 15 to 135 minutes) (Lumry 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action: Time to complete resolution of hereditary angioedema (HAE) symptoms: Berinert: Median: 8.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Berinert: V<sub>ss</sub>: Children and Adolescents: (6 to 13 years, n=5): 0.02 L/kg (range: 0.017 to 0.026 L/kg); Adults: 0.018 L/kg (range: 0.011 to 0.028 L/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Haegarda: V<sub>d</sub>: Adolescents and Adults: 0.05 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Haegarda: 42.7%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Berinert:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (6 to 13 years, n=5): 22 hours (range: 20 to 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults (following a single dose): 22 hours (range: 17 to 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cinryze: Adults: 56 hours (range: 11 to 108 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Haegarda: Adolescents and Adults: 69 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Cinryze: ~4 hours; Haegarda: 59 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7715640\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Cinryze: 1 unit corresponds to C1 inhibitor present in 1 mL of normal fresh plasma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Berinert: A single 500 unit vial contains 400-625 units of C1 inhibitor </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321852\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Berinert Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (1): $3,378.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cinryze Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (1): $3,310.55</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Haegarda Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (1): $2,256.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (1): $3,384.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23672322\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Berinert (AT, AU, BE, CH, CY, CZ, DK, ES, FI, FR, GB, HU, IL, KR, LU, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR);</li>\n      <li>Berinert P (AR, JP);</li>\n      <li>Cinryze (CZ, DK, EE, GB, IS, LT, MT, NO, PL, SE, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Baker JW, Craig TJ, Riedl MA, et al, &quot;Nanofiltered C1 Esterase Inhibitor (Human) for Hereditary Angioedema Attacks in Pregnant Women,&quot; <i>Allergy Asthma Proc</i>, 2013, 34(2):162-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/c1-esterase-inhibitor-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/23484892/pubmed\" target=\"_blank\" id=\"23484892\">23484892</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berinert (C1 Esterase Inhibitor [Human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caballero T, Farkas H, Bouillet L, et al, &quot;International Consensus and Practical Guidelines on the Gynecologic and Obstetric Management of Female Patients With Hereditary Angioedema Caused by C1 Inhibitor Deficiency,&quot; <i>J Allergy Clin Immunol</i>, 2012, 129(2):308-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/c1-esterase-inhibitor-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/22197274/pubmed\" target=\"_blank\" id=\"22197274\">22197274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cinryze (C1 esterase inhibitor [human]) [prescribing information]. Lexington, MA: Shire ViroPharma Biologics; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haegarda (C1 Esterase Inhibitor [Human]) [prescribing information]. Kankakee, IL: CSL Behring LLC; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hermans C, &quot;Successful Management With C1-Inhibitor Concentrate of Hereditary Angioedema Attacks During Two Successive Pregnancies: A Case Report,&quot; <i>Arch Gynecol Obstet</i>, 2007, 276(3):271-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/c1-esterase-inhibitor-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/17653743/pubmed\" target=\"_blank\" id=\"17653743\">17653743</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lumry W, Manning ME, Hurewitz DS, et al, &quot;Nanofiltered C1-Esterase Inhibitor for the Acute Management and Prevention of Hereditary Angioedema Attacks Due to C1-Inhibitor Deficiency in Children,&quot; <i>J Pediatr</i>, 2013, 162(5):1017-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/c1-esterase-inhibitor-concentrate-from-human-plasma-pediatric-drug-information/abstract-text/23312695/pubmed\" target=\"_blank\" id=\"23312695\">23312695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wasserman RL, Levy RJ, Bewtra AK, et al, &quot;Prospective Study of C1 Esterase Inhibitor in the Treatment of Successive Acute Abdominal and Facial Hereditary Angioedema Attacks,&quot; <i>Ann Allergy Asthma Immunol</i>, 2011, 106(1):62-8.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16458 Version 82.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6759053\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13261898\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F7715627\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F7715637\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6764799\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F6764774\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11368727\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7715638\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F6764787\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7715628\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6764808\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6764780\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6764781\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298919\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6764785\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F6764777\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6764778\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F11598643\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6764789\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F6764790\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F7715640\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321852\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23672322\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16458|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=c1-esterase-inhibitor-concentrate-from-human-plasma-drug-information\" class=\"drug drug_general\">C1 esterase inhibitor, concentrate from human plasma: Drug information</a></li><li><a href=\"topic.htm?path=c1-esterase-inhibitor-concentrate-from-human-plasma-patient-drug-information\" class=\"drug drug_patient\">C1 esterase inhibitor, concentrate from human plasma: Patient drug information \t</a></li></ul></div></div>","javascript":null}